Clinical trial · Interventional
The Tomosynthesis Trial in Bergen - Part 2
Digital Breast Tomosynthesis - The Future Screening Tool for Breast Cancer?
NCT03669926CI-TRIAL-00080283To-Be 2completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to compare early performance measures and economic aspects of organized breast cancer screening for women screened using digital breast tomosynthesis+synthetic mammography (DBT+SM) to women with a prior DBT+SM or digital mammography (DM) from To-Be 1 (NCT02835625).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Digital Breast Tomosynthesis+synthetic mammography | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- DBT+SM
- description
- Digital Breast Tomosynthesis+synthetic mammography (DBT+SM) All women are screened with DBT+SM. All examinations are independently double read. Consensus used to decide whether or not to recall.
- interventionNames
- Radiation: Digital Breast Tomosynthesis+synthetic mammography
Primary outcomes (1)
- measure
- Compare rates of screen detected breast cancer after subsequent screening with DBT+SM after DBT+SM versus screening with DBT+SM after prior DM, as performed in a population based screening program.
- timeFrame
- 48 months from start up of the trial
- description
- Rate of screening detected breast cancer, among those screened
Secondary outcomes (8)
- measure
- Compare recall rates after subsequent screening with DBT+SM after DBT+SM versus screening with DBT+SM after prior DM, as performed in a population based screening program.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 48 Years
- Maximum age
- 71 Years
Show eligibility criteria text
Inclusion Criteria: * Written, informed consent to participation Exclusion Criteria: * No written, informed consent to participation * Breast implants
References
Publications (0)
Data not yet available
No reference posted for this study.